CN110882302B - Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor - Google Patents
Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor Download PDFInfo
- Publication number
- CN110882302B CN110882302B CN201811042449.9A CN201811042449A CN110882302B CN 110882302 B CN110882302 B CN 110882302B CN 201811042449 A CN201811042449 A CN 201811042449A CN 110882302 B CN110882302 B CN 110882302B
- Authority
- CN
- China
- Prior art keywords
- natural composition
- xanthine oxidase
- uric acid
- hydrolysate
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses a natural composition for reducing uric acid, application thereof and a xanthine oxidase inhibitor, wherein the natural composition comprises cortex cinnamomi, liquorice and dried guava, wherein the cortex cinnamomi, the liquorice and the dried guava are subjected to hydrolysis engineering treatment, no enzyme or ethyl acetate is added in the process, and the natural composition can be further added with pharmaceutically acceptable carriers, excipients, diluents or anti-inflammatory agents or used together with other health-care foods or medicines related to uric acid reduction; the natural composition can be used as a xanthine oxidase inhibitor, or can be used for preparing a pharmaceutical composition for improving diseases related to hyperuricemia or a pharmaceutical composition for preparing diseases using the xanthine oxidase inhibitor.
Description
Technical Field
The invention relates to the field of natural compositions, in particular to a natural composition for reducing uric acid, application thereof and a xanthine oxidase inhibitor.
Background
Uric acid (uric acid) is a final metabolite of purine produced by xanthine oxidase through layer-by-layer enzyme action in human body, and when the influence of environment, heredity or living habits causes the decrease of uric acid excretion or the excessive production of uric acid, a state of hyperuricemia in blood is formed, which is called hyperuricemia, and the disease is often complicated by other diseases, such as: gout, recurrent gout attack, gouty arthritis, nephropathy, kidney stones, renal failure, joint inflammation, arthritis, urolithiasis and the like, wherein gout is a representative complication, is an inflammatory disease caused by sodium urate deposition, causes inconvenience in activities of patients, often causes great inconvenience on living quality, and even is accompanied with other complications such as hypertension, kidney failure, arteriosclerosis, coronary heart disease, type II diabetes mellitus, hyperlipidemia and the like if the concentration of uric acid in blood is not properly controlled, so that hyperuricemia is a disease which cannot be neglected, and in recent years, the patients tend to increase year by year due to changes in dietary life, so that how to prevent, control and reduce uric acid becomes a high concern of the public.
Current approaches to treating hyperuricemia or gout include reducing the uric acid concentration in the blood using urate-lowering agents: xanthine oxidase inhibitors, such as isopurinol (allopurinol) and febuxostat (febuxostat); uricosuric agents, such as fensulazolone (sulphopyrazone), benzbromarone (benzbromarone), and probenecid (probenecid); urate oxidases, such as pegylated recombinant uricase (pegloticase), purecase (puricase), rasburiase (rasburiase), and pegylated uricase (pegylated uricase); fenofibrate (fenofibrate). In addition, the symptoms of acute gout are often controlled using anti-inflammatory agents, such as: nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin (indomethacin) and ibuprofen (ibuprofen); corticosteroids (corticosteriod); colchicine (colchicine).
However, current drug treatments often cause a variety of adverse side effects. For example, xanthine oxidase inhibitors (e.g., allopurines) can cause allergic vasculitis, Stevens-Johnson syndrome, exfoliative dermatitis, aplastic anemia, and hepatic insufficiency; uricosuric agents (e.g., probenecid, bucolome, and benzbromarone) may cause gastrointestinal disturbances, urolithiasis, and fulminant liver failure in patients with specific physical conditions.
Therefore, it is a direction of thinking and trying for those skilled in the art to find a natural substance or a natural composition having no side effects and excellent therapeutic effect of reducing hyperuricemia.
The current relevant patent documents are listed below:
taiwan patent publication No. TW 201406383 discloses a Chinese medicinal composition for treating muscular atrophy, condyle deformation and gout, which comprises a series of Chinese medicinal materials, wherein the Chinese medicinal materials comprise licorice root, and can recover atrophic and weak muscles to different degrees, prevent muscular atrophy and condyle deformation, and improve symptoms of uric acid gout.
Chinese patent publication No. CN 104127764A discloses a Chinese medicine for reducing uric acid and treating gout by regulating metabolism, which comprises a compound of 25 Chinese medicinal materials including cortex Cinnamomi and Glycyrrhrizae radix.
Related documents show that most of the composition compounds for reducing uric acid or treating gout from natural substances are traditional Chinese medicine compounds, the selection and preparation of raw materials are difficult and complicated, the individual effects of the raw materials in the composition compounds are unknown, the differences of the composition proportion of the composition compounds relative to the effects are unknown, and the mechanism of the components of the compound is unclear.
Therefore, the problem to be solved by the present invention is how to provide a natural composition which has no side effect, has excellent effect of reducing high uric acid, and has the advantages of clear mechanism of compound components and easy acquisition of components.
Disclosure of Invention
Based on the problems existing in the existing scheme, the invention provides a natural composition for reducing uric acid, application thereof and a xanthine oxidase inhibitor, which are used for reducing uric acid and improving gout.
The invention provides a natural composition for reducing uric acid, which comprises cortex cinnamomi, liquorice and dried guava.
According to the xanthine oxidase inhibition experiment shown in the embodiment, the cinnamomum cassia, the liquorice or the guava are proved to have the xanthine oxidase inhibition capacity, wherein the cinnamomum cassia is a primary Taiwan original species in the cinnamomum genus, and the effect is firstly provided, and the xanthine oxidase inhibition effect is better than that of the liquorice and the guava.
In addition, the combination of the three natural substances is firstly proposed to have better effect than any single species, and the effect of the combination of the natural substances also has double effect, and the weight percentage of the better composition is disclosed, and the composition effect can not be directly obtained by the proportion of the single species with better inhibition effect.
Optionally, cortex cinnamomi, radix glycyrrhizae, and dried guava are all processed by a hydrolysis process, in which no enzyme or ethyl acetate is added, and the hydrolysis process of the natural composition comprises the following steps:
the method comprises the following steps: respectively adding extract powder of cinnamomum cassia, liquorice and dried guava in a predetermined weight percentage into a mixed solution containing ethanol and hydrochloric acid, and performing hydrolysis reaction for 3-5 hours at 60-80 ℃;
step two: the reaction solution was concentrated in vacuo, and then lyophilized to obtain a hydrolysate, which was in the form of powder.
Optionally, in the natural composition provided by the invention, the reaction condition of the hydrolysis reaction is 70 ℃, and the reaction time of the hydrolysis reaction is 4 hours.
The invention firstly uses a new hydrolysis engineering technology on the extract for inhibiting the xanthine oxidase, further breaks through the defects that the prior hydrolysis engineering needs to add enzyme or highly-harmful organic solvent (such as ethyl acetate) and needs complicated processes, has the advantages of simplicity and convenience, and the product after hydrolysis treatment has no harm to the body and has better effect on inhibiting the xanthine oxidase.
The natural composition provided by the invention achieves the effect of reducing uric acid by inhibiting xanthine oxidase, and is applied to treating diseases related to high uric acid, and the diseases related to high uric acid can be selected from the following disease types or disease combination: hyperuricemia, gout, recurrent gout attacks, gouty arthritis, nephropathy, kidney stones, renal failure, joint inflammation, arthritis, and urolithiasis, the above compositions have a very wide and widespread application value in the treatment of diseases.
The natural composition provided by the invention comprises 30-50% of cortex cinnamomi, 15-40% of liquorice and 20-50% of dried guava in percentage by weight.
The composition can be prepared into health-care food or medicine because no side effect exists except the existence of natural substances, and comprises the addition of pharmaceutically acceptable carrier, excipient, diluent or anti-inflammatory agent, or is combined with other health-care food or medicine for reducing uric acid or inhibiting xanthine oxidase, and the composition is combined with the existing common treatment scheme to achieve the functions of assisting and improving the curative effect.
The invention also provides a xanthine oxidase inhibitor which comprises the natural composition.
The invention also provides a natural composition containing cortex cinnamomi, liquorice and guava stem, and the natural composition has the application of preparing a medicinal composition for improving diseases related to hyperuricemia, wherein the diseases related to the hyperuricemia can be selected from the following disease types or the disease combination: hyperuricemia, gout, recurrent gout attacks, gouty arthritis, nephropathy, kidney stones, renal failure, joint inflammation, arthritis, and urolithiasis.
The invention also provides a natural composition containing cortex cinnamomi, liquorice and dried guava, and the natural composition has the application of preparing a medicinal composition for diseases requiring the use of xanthine oxidase inhibitors.
The composition has the function of inhibiting xanthine oxidase, so that the composition can be applied to other related diseases needing to use xanthine oxidase inhibitors besides reducing uric acid, and has the potential of diversified application in the application of health-care food or medicines.
Drawings
FIG. 1 shows the inhibition of xanthine oxidase by cinnamon, licorice and guava dry hydrolysate.
FIG. 2 shows the inhibition ratios of xanthine oxidase by compositions A, B, C and D.
Detailed Description
All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, unless otherwise defined.
As used herein, the term "natural product" refers to a substance derived from animals or plants in nature, not synthesized by humans; the term "extract" refers to the product produced by extraction, which may be present as a solution in a solvent, or as a concentrate or concentrate free or substantially free of solvent, as a single extract obtained from a particular extraction step or series of extraction steps, or as a combination of extracts obtained from separate extraction steps; the term "hydrolysate" refers to a product of an extract or a natural product subjected to a hydrolysis process shown below, the hydrolysate being in a powder form; the term "IC 50," also known as half inhibitory concentration, refers to half the amount (or concentration) of a substance (inhibitor) that is required to inhibit a biological process, and half the concentration of the extract or hydrolysate when applied to completely inhibit xanthine oxidase.
The invention is illustrated but not limited by the following examples, all of which are commercially available and readily available.
Example one
In order to clarify the inhibition effect of each natural product on xanthine oxidase by each single and each ratio combination, firstly, the natural product is obtained and extracted and hydrolyzed. The natural materials are cortex Cinnamomi from Taiwan, the cortex Cinnamomi is a special species of Taiwan, and radix Glycyrrhizae and dried fructus Psidii Guajavae Immaturus are used as raw materials.
In the implementation, the extraction engineering is specifically operated as follows:
weighing cortex cinnamomi, radix Glycyrrhizae, and dried fructus Psidii Guajavae Immaturus, each 100 g, adding into 1.0L (L) 50% ethanol, extracting at 50 deg.C for 4 hr, filtering to remove residue, vacuum concentrating the filtrate, and freeze drying to obtain powdered extract.
In the implementation, the hydrolysis engineering is specifically operated as follows:
accurately weighing 20 milligrams (mg) of each extract of cortex cinnamomi, radix glycyrrhizae, and dried guava, adding 8 milliliters (ml) of 95% ethanol and 2ml of 4M Hydrochloric acid (HCl for short), hydrolyzing at 60-80 ℃ for 3-5 hours, concentrating under vacuum, and freeze-drying to obtain powdery hydrolysate, wherein the hydrolysis is carried out at 70 ℃ for 4 hours.
Each hydrolysate was further formulated into compositions A to D according to Table 1, and the formulation of the solution to be tested and the standard was continued.
TABLE 1
In the implementation, the preparation method of the solution to be detected and the standard substance is as follows:
in terms of a solution to be detected, hydrolysates and extracts of cinnamomum cassia, liquorice and dried guava or compositions A to D are accurately weighed, wherein the respective dosages are 102.4 mg, 1.0ml of Dimethyl sulfoxide (DMSO for short) is added, and the Dimethyl sulfoxide is diluted by a two-fold sequence to obtain nine groups of intervals with the concentration of 0.4-102.4 mg/ml;
allopurine (allopurine) standard, purchased from sigma, was prepared by adding 3.2mg to 1.0ml of 0.2M Phosphate buffered saline (hereinafter referred to as PBS), and diluting the mixture in the same manner by a double-fold sequence to obtain nine sets of concentration ranges of 0.0125 to 3.2 (mg/ml).
In practice, the preparation method of the Xanthine (Xanthine) solution is as follows:
xanthine (95 mg) was precisely weighed, dissolved in a small amount of Sodium Hydroxide (NaOH) solution, adjusted to pH 7.5 with sterilized 0.2M PBS in a volume of 100ml, 10ml of the solution was taken out, adjusted to 1000ml with sterilized 0.2M PBS, and filtered through a 0.45 μ M filter to obtain 62.5 μ M xanthine solution.
In practice, the preparation method of the xanthine oxidase solution is as follows:
a xanthine oxidase solution (0.625U/ml) was prepared by diluting 40. mu.l (1U) of xanthine oxidase with PBS to 1.6 ml.
Xanthine oxidase inhibition experiments were performed, the experimental procedures are as follows:
step 1, taking 10 mu L of xanthine oxidase liquid and 1.960mL of PBS to be respectively and uniformly mixed with 30 mu L of cortex cinnamomi, liquorice and guava dry solution to be tested or standard substance in each concentration range, supplementing 30 mu L of DMSO into blank groups without adding any object to be tested or standard substance, finally adding 1mL of xanthine liquid into each group, reacting for 15 minutes at 30 ℃, measuring by using UV wavelength 295nm, and repeating the steps for three times to obtain an average value.
And 2, calculating the inhibition rate by the following formula.
A1 is the absorbance of each group containing xanthine oxidase.
A2 is the absorbance of each group without xanthine oxidase.
A0 is the change in absorbance (absorbance with xanthine oxidase to absorbance without xanthine oxidase) when the sample is not contained in the sample.
And 3, calculating the IC50 by using the xanthine oxidase inhibition rate through software.
Results 1: the single hydrolysate has xanthine oxidase inhibiting effect.
As shown in fig. 1, in the concentration interval of the solution to be tested from 128 μ g/ml to 1024 μ g/ml, the hydrolysates of cinnamomum cassia, glycyrrhiza, and guava all have the inhibitory effect on xanthine oxidase, and when the concentration is 64 μ g/ml, the hydrolysates of cinnamomum cassia and glycyrrhiza have the inhibitory rate of 50.1% and 23.1% respectively, while the hydrolysates of guava have the poor inhibitory effect and the inhibitory rate of 3.3%, in the sequence of the inhibitory effects of the three, the best hydrolysate is cinnamomum cassia, glycyrrhiza, guava, and the inhibitory rate of the hydrolysates of the three on xanthine oxidase increases with the increase of the concentration.
Results 2: the hydrolysate and hydrolyzed composition have xanthine oxidase inhibiting effect.
As shown in FIG. 2, when the concentration is 64 μ g/mL, the inhibition of xanthine oxidase by composition A is poor, and the inhibition rate is 25.3%, while the inhibition rate of composition B, C, D is 56.7%, 53.6% and 55.4%, respectively; wherein, because the content of cinnamon and licorice containing a higher proportion of better xanthine oxidase inhibition efficacy is 40% and 34%, respectively, which are obviously higher than 32% and 18% of composition C, the xanthine oxidase inhibition rate of composition A is significantly lower than that of composition C, which shows that the composition does not contain a higher proportion of hydrolysate (such as cinnamon and licorice) having better inhibition efficacy, the better xanthine oxidase inhibition efficacy can be obtained, and the inhibition effect can be confirmed by further experiments.
As shown in table 2, IC50 of each group is shown, i.e. the lower the concentration of the compound reaches to inhibit half of the xanthine oxidase, the better the inhibitory effect is shown, and as the previous inhibitory rate results, cinnamomum cassia and glycyrrhiza hydrolysate have better inhibitory effect on xanthine oxidase, IC50 is 69.08 and 123.6 μ g/mL respectively, and guava dry hydrolysate has worse inhibitory effect of 407.9 μ g/mL.
TABLE 2
In one aspect, the hydrolyzed compositions, as analyzed by IC50, were similar to, or even better than, either of compositions a-D, compared to either hydrolysate alone, with composition D being the most preferred and IC50 being 56.79 μ g/mL, indicating that the compositions at this particular ratio had better inhibitory efficacy compared to the single species.
On the other hand, comparing the inhibition effect of the hydrolysis engineering of the invention on xanthine oxidase, it can be seen that the IC50 of the unhydrolyzed extracts of the three natural products is significantly higher than that of the group treated by the hydrolysis engineering, and thus, the inhibition effect of each natural product on xanthine oxidase can be improved by the hydrolysis engineering treatment of the invention.
According to the embodiment of the invention, xanthine oxidase inhibition experiments prove that cortex cinnamomi, liquorice or guava have the xanthine oxidase inhibition capability, wherein the cortex cinnamomi is an original Taiwan strain, is firstly proposed to have the inhibition effect and is superior to the liquorice and the guava.
In addition, the invention firstly provides a combination of three natural substances, which has better effect and addition effect compared with a single species, the proportion of the single species with better inhibition effect in the composition can not be directly deduced, and experiments still need to prove that the effect of the composition can not consist of the single species, and the hydrolysate of the hydrolysis engineering has better inhibition effect on the xanthine oxidase, and the hydrolysis engineering of the invention breaks through the well-known technology of adding enzyme or highly-harmful organic solvent (such as ethyl acetate) or needing complicated processes, thereby having the advantages of simplicity, convenience, no harm to the body of products and improvement on the inhibition effect on the xanthine oxidase.
The composition provided by the invention has the advantages of natural property, no harm to human bodies, high efficiency and the like of xanthine oxidase inhibition capability, and the xanthine oxidase is a key enzyme for producing uric acid, so the composition has the effect of reducing uric acid by inhibiting the xanthine oxidase, and can be further applied to treating diseases related to hyperuricemia by reducing the uric acid, and the diseases related to hyperuricemia can be selected from the following disease types or the combination of the disease types: hyperuricemia, gout, recurrent gout attacks, gouty arthritis, nephropathy, kidney stones, renal failure, joint inflammation, arthritis, and urolithiasis, all of which are areas of the art that may be derived from embodiments of the present invention.
Besides the existence of natural substances, the composition of the invention can be used in any derived applications associated with health food or medicines, including the addition of pharmaceutically acceptable carriers, excipients, diluents, anti-inflammatory agents, or in combination with other health food or medicines for reducing uric acid or inhibiting xanthine oxidase, and is also within the scope of application implied by the embodiment of the invention.
Any use of the composition of the present invention to improve hyperuricemia or related diseases requiring the use of xanthine oxidase inhibitors is also encompassed by the scope of the present invention.
The foregoing embodiments are provided merely to illustrate the technical spirit and features of the present invention, and it is an object of the present invention to enable those skilled in the art to understand the content of the present invention and to implement it accordingly, and various changes and modifications can be made without departing from the spirit and scope of the present invention, i.e., it is intended to cover within the scope of the present invention all such changes and modifications as may be made in accordance with the spirit of the present invention.
Claims (9)
1. The natural composition for reducing uric acid is characterized by being prepared from the following raw materials through extraction engineering and hydrolysis engineering treatment:
cortex Cinnamomi, Glycyrrhrizae radix and dried fructus Psidii Guajavae Immaturus;
wherein the extraction process comprises:
weighing cortex cinnamomi, radix glycyrrhizae and dried guava respectively, adding into 50% ethanol for extraction, filtering, concentrating, and freeze-drying to obtain powdery extract;
the hydrolysis engineering treatment process does not add ferment or ethyl acetate, and comprises the following steps:
the method comprises the following steps: respectively adding extract powder of cinnamomum zeylanicum, liquorice and dried guava into a mixed solution containing 95% ethanol and 4M hydrochloric acid, and performing hydrolysis reaction at 60-80 ℃ for 3-5 hours;
step two: concentrating the reaction solution in vacuum, and freeze-drying to obtain a hydrolysate, wherein the hydrolysate is in a powder form;
30-50% of cinnamon hydrolysate, 15-40% of licorice hydrolysate and 20-50% of dried guava hydrolysate.
2. The natural composition according to claim 1, wherein the reaction conditions of the hydrolysis reaction are 70 ℃ and the reaction time of the hydrolysis reaction is 4 hours.
3. The natural composition of claim 1 wherein said natural composition achieves uric acid reduction by inhibiting xanthine oxidase.
4. The natural composition according to claim 1, wherein the natural composition is used for treating diseases related to high uric acid by reducing uric acid, and the diseases related to high uric acid are selected from any one or more of the following disease types in combination: hyperuricemia, gout.
5. The natural composition of claim 1 wherein said cinnamon hydrolysate is 48%, said licorice hydrolysate is 28%, and said guava dry hydrolysate is 24%.
6. The natural composition according to claim 1, wherein the natural composition further comprises pharmaceutically acceptable excipients, or the natural composition is used in combination with other health foods or drugs for reducing uric acid.
7. A xanthine oxidase inhibitor, which is the natural composition according to any one of claims 1 to 6.
8. Use of a natural composition according to any one of claims 1 to 6 in the preparation of a medicament for lowering uric acid.
9. Use of the xanthine oxidase inhibitor according to claim 7 in the manufacture of a medicament for the production of a xanthine oxidase inhibitor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811042449.9A CN110882302B (en) | 2018-09-07 | 2018-09-07 | Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811042449.9A CN110882302B (en) | 2018-09-07 | 2018-09-07 | Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110882302A CN110882302A (en) | 2020-03-17 |
| CN110882302B true CN110882302B (en) | 2021-12-03 |
Family
ID=69744469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811042449.9A Active CN110882302B (en) | 2018-09-07 | 2018-09-07 | Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110882302B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209062A (en) * | 2021-12-24 | 2022-03-22 | 湖州中科营养与健康创新中心 | Functional food for reducing blood sugar |
| CN114190560A (en) * | 2021-12-24 | 2022-03-18 | 湖州中科营养与健康创新中心 | Uric acid-reducing functional food and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201026370A (en) * | 2009-01-12 | 2010-07-16 | Chaoyang University Of Technologytw | Method for extracting cinnamon leaf soil flavonoid sugar glycosides compound |
| CN101925361A (en) * | 2008-01-23 | 2010-12-22 | 株式会社钟化 | Plant-origin drug for preventing or improving hyperuricemia |
| CN102083449A (en) * | 2008-07-07 | 2011-06-01 | 花王株式会社 | Xanthine oxidase inhibitor and uric acid production inhibitor |
| CN103558306A (en) * | 2013-10-31 | 2014-02-05 | 中南大学 | Composite for screening xanthine oxidase inhibitor and application method thereof |
-
2018
- 2018-09-07 CN CN201811042449.9A patent/CN110882302B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101925361A (en) * | 2008-01-23 | 2010-12-22 | 株式会社钟化 | Plant-origin drug for preventing or improving hyperuricemia |
| CN102083449A (en) * | 2008-07-07 | 2011-06-01 | 花王株式会社 | Xanthine oxidase inhibitor and uric acid production inhibitor |
| TW201026370A (en) * | 2009-01-12 | 2010-07-16 | Chaoyang University Of Technologytw | Method for extracting cinnamon leaf soil flavonoid sugar glycosides compound |
| CN103558306A (en) * | 2013-10-31 | 2014-02-05 | 中南大学 | Composite for screening xanthine oxidase inhibitor and application method thereof |
Non-Patent Citations (7)
| Title |
|---|
| Biological study of the effect of licorice roots extract on serum lipid profile，liver enzymes and kidney function tests in albino mice;Maysoon等;《African Journal of Biotechnology》;20111003;第10卷(第59期);第12702-12706页，尤其是第12704页左栏第2段 * |
| Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice;S.Y.Wang等;《Phytomedicine》;20081231;第940-945页，尤其是第940页摘要部分 * |
| Kaempferol glycosides from the twigs of Cinnamomum osmophloeum;Huan-You等;《Carbohydrate Research》;20121022;第49-53页 * |
| Novel Insights into the Inhibitory Mechanism of Kaempferol on Xanthine Oxidase;Yajie Wang等;《Agricultural and food chemistry》;20151231;第526-534页 * |
| The effect of red guava juice (Psidium guajava Linn.) in decreasing uric acid and creatinine levels of hyperuricemic white mice (Mus musculus);Aprilinda等;《Bali Medical Journal》;20181231;第7卷(第2期);第323-329页 * |
| 异甘草素对黄嘌呤氧化酶抑制的影响及机制;张瑞城等;《中国老年学杂志》;20150930;第35卷;第4757-4758页 * |
| 酸水解法提取甘草中异甘草素工艺研究;付玉杰等;《中国药学杂志》;20070630;第42卷(第11期);第818-821页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110882302A (en) | 2020-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5538611B2 (en) | Maillard reaction inhibitor | |
| CN105395577B (en) | A kind of anti-trioxypurine composition and its preparation | |
| CN110882302B (en) | Natural composition for reducing uric acid, application thereof and xanthine oxidase inhibitor | |
| CN108392518B (en) | Toona sinensis extract and preparation method and application thereof | |
| CN113368248A (en) | Composition for protecting cells comprising cyclamic acid-proline as active ingredient | |
| CN105727144A (en) | Traditional Chinese medicine composition for treating bronchitis and preparation method thereof | |
| CN103919857A (en) | Folium eucalypti extractive with uric acid reduction effect as well as preparation method and application thereof | |
| CN103417601A (en) | Pharmaceutical composition capable of adjusting blood fat and applications thereof | |
| CN111533770A (en) | Preparation method of arbutin in sparrow tea and application of arbutin in treating hyperuricemia | |
| WO2017129058A1 (en) | Medicament for use in treating gout | |
| CN103860638A (en) | Preparation method of sophora alopecuroide flavonoid composition and new medical application | |
| CN104224863B (en) | Lysimachia herb total flavone is preparing the application in treating antihyperuricemic disease drug | |
| CN104983729B (en) | Catechin compounds and gallic acid combination are preparing the new application in treating antihyperuricemic disease drug | |
| CN108815218B (en) | Pharmaceutical composition and use thereof | |
| TWI715865B (en) | A natural composition with inhibiting xanthine oxidase activity and its use for reducing uric acid and gout | |
| CN112592328B (en) | Diaryl heptane-chalcone polymer in alpinia katsumadai, and pharmaceutical composition and application thereof | |
| CN109394798B (en) | Preparation method of dried extract of xanthobacter guidongensis and application of dried extract in reducing uric acid | |
| WO2009135351A1 (en) | The use of the extract of prunus mume for preparation of compositions | |
| CN101099765B (en) | Preparation method of Chaihuang preparation | |
| CN1371920A (en) | Persimmon leaf polysaccharide and biological activity thereof | |
| JP2006016340A (en) | Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient | |
| CN112674327B (en) | Health-care food | |
| JP2015151362A (en) | Osteoarthritis improver | |
| CN109106731B (en) | Preparation method of coriolus versicolor extract and application of coriolus versicolor extract in reducing uric acid | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |